Clinical Trial Update: Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and Children [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating the safety and immunogenicity of a Human Parainfluenza Virus Type 3 vaccine in infants and children has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parainfluenza Virus Infection
• Parainfluenza Virus Type 3 Infection

Drugs mentioned

• HPIV3 vaccine candidate

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Parainfluenza Virus 3, Human | Phase 1 | Status: COMPLETED